Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma

MLA

Koen van Besien, et al. “Updated Analysis of CALGB 100104 (Alliance): A Randomised Phase III Study Evaluating Lenalidomide vs Placebo Maintenance after Single Autologous Stem Cell Transplant for Multiple Myeloma.” The Lancet. Haematology, vol. 4, no. 9, Aug. 2017, pp. e431–42. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5885770bf20d691c1eaaba4dba197a56&authtype=sso&custid=ns315887.

APA

Koen van Besien, David D. Hurd, Kouros Owzar, Vera Hars, Thomas Martin, Edward A. Stadtmauer, Marcia Wilson, Charles A. Linker, Asad Bashey, Molly Boyd, Sarah A. Holstein, Ravi Vij, Teresa Gentile, Heather Landau, Mary M. Horowitz, Natalie S. Callander, Luis Isola, Philip L. McCarthy, Robert L. Schlossman, … Sergio Giralt. (2017). Updated analysis of CALGB 100104 (Alliance): a randomised phase III study evaluating lenalidomide vs placebo maintenance after single autologous stem cell transplant for multiple myeloma. The Lancet. Haematology, 4(9), e431–e442.

Chicago

Koen van Besien, David D. Hurd, Kouros Owzar, Vera Hars, Thomas Martin, Edward A. Stadtmauer, Marcia Wilson, et al. 2017. “Updated Analysis of CALGB 100104 (Alliance): A Randomised Phase III Study Evaluating Lenalidomide vs Placebo Maintenance after Single Autologous Stem Cell Transplant for Multiple Myeloma.” The Lancet. Haematology 4 (9): e431–42. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5885770bf20d691c1eaaba4dba197a56&authtype=sso&custid=ns315887.